Ardelyx Reports IBSRELA Reduces Healthcare Visits in IBS-C Patients
Reuters
Oct 28, 2025
<a href="https://laohu8.com/S/ARDX">Ardelyx</a> Reports IBSRELA Reduces Healthcare Visits in IBS-C Patients
Ardelyx Inc. has announced the presentation of new clinical data supporting the benefits of its drug IBSRELA® (tenapanor) at the American College of Gastroenterology's 2025 Annual Scientific Meeting. The results, which have already been presented, include a post-hoc analysis of T3MPO-1 and T3MPO-2 studies demonstrating the effectiveness of IBSRELA in reducing abdominal bloating for patients with irritable bowel syndrome with constipation (IBS-C). Additionally, a real-world survey indicated patient treatment satisfaction, and an analysis of electronic health records suggests that initiation of IBSRELA may lead to a reduction in gastrointestinal-related clinical visits and patient portal messaging among patients with high pre-treatment healthcare resource utilization. These findings suggest a potential reduction in healthcare system burden and possible cost savings. Poster presentations are publicly available on demand.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ardelyx Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9563115-en) on October 28, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.